1. Home
  2. CTRM vs BCDA Comparison

CTRM vs BCDA Comparison

Compare CTRM & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.25

Market Cap

21.6M

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$0.91

Market Cap

17.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
BCDA
Founded
2016
N/A
Country
Cyprus
United States
Employees
N/A
21
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
17.9M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CTRM
BCDA
Price
$2.25
$0.91
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
41.1K
833.7K
Earning Date
04-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.78
52 Week High
$2.65
$2.45

Technical Indicators

Market Signals
Indicator
CTRM
BCDA
Relative Strength Index (RSI) 54.28 41.35
Support Level $1.95 $0.81
Resistance Level $2.43 $1.32
Average True Range (ATR) 0.14 0.11
MACD 0.01 -0.00
Stochastic Oscillator 46.59 21.21

Price Performance

Historical Comparison
CTRM
BCDA

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segment, and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: